Streptococcus Pyogenes

Major obstacles in the development of vaccines to S. pyogenes have been its genomic heterogenicity and high sequence homology with human proteins.


Streptococcus pyogenes (GAS) is a Gram-positive pathogen estimated to cause 700 million infections per annum worldwide. While GAS is primarily responsible for mild symptoms such as strep throat, it may also cause life-threatening conditions such as necrotizing fasciitis (also called flesh-eating disease), toxic shock syndrome and other post-infectious immune-related diseases.

The emergence of GAS antimicrobial resistance against antibiotics such as penicillin, clindamycin and macrolides has led the WHO to flag the development of a global vaccine against GAS as a priority in their agenda.

Our Research

With a focus on combatting the development of antimicrobial resistance (AMR), we are completing lead optimisation studies with a view to taking RVX-003 into preclinical studies in Q2 2023.

Get in touch

To learn more about our RVX-003 Streptococcus Pyogenes vaccine please click on the below button